Agios Presents Updated PYRUKYND® (mitapivat) Data
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependent α- or...
Source: globenewswire.com
Actively Enrolling Phase News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Actively Enrolling Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Actively Enrolling Phase Today - Breaking & Trending Today
Agios Announces Publication of Phase 2 Data in The Lancet Demonstrating Safety and Efficacy of PYRUKYND (mitapivat) in Non-transfusion-dependent α- and β-Thalassemia
12.08.2022 - – In Adults with Non-transfusion-dependent α- or β-Thalassemia, PYRUKYND Induced ≥1.0 g/dL Hemoglobin Increase from Baseline in 16 of 20 (80%) Patients Between Weeks 4-12 – – PYRUKYND Safety Profile Consistent with Label for FDA-approved Indication ... Seite 1
Source: wallstreet-online.de